CEO Soriot said Europe must boost investment in pharma innovation or risk falling further behind the US in drug development.

Discover AstraZeneca's Q1 2025 performance with 10% revenue growth, innovative medicines, and bold 2030 goals.

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

AstraZeneca (AZN) halts Truqap trial for prostate cancer after an independent review finds it unlikely to meet survival or ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

Some telehealth companies that offered compounded GLP-1s have disappeared altogether. Others are pursuing strategies that ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Dana Cimilluca is former Wall Street bureau chief at The Wall Street Journal, where he managed a group of reporters and editors covering banks, hedge funds, private-equity firms, M&A and IPOs. He ...

Eli Lilly ( NYSE:LLY) is the most valuable healthcare company, with UnitedHealth Group ( NYSE:UNH) and Johnson & Johnson ( ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best UK stocks to invest in. Like most of the world, the United Kingdom is also facing ...